{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T16:20:50Z","timestamp":1790785250931,"version":"4.1.0"},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"38","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>\n                      Although serum magnesium (Mg) levels are closely associated with the prognosis of heart failure (HF) patients, the clinical significance of sMg levels on the cardiovascular outcomes of HF with preserved ejection fraction (HFpEF) patients is not fully understood. This study was a retrospective, single-center, observational study. We enrolled 452 consecutive HFpEF patients admitted to Kumamoto University Hospital. We defined lower sMg as &lt;2.0\u200amg\/dl (=0.8\u200ammol\/L) based on recent clinical evidence and compared their clinical characteristics and prognosis. There were no significant differences between groups in the use of all medications (loop diuretics, mineralocorticoid receptor antagonists, renin-angiotensin-aldosterone system inhibitors, calcium channel blockers, beta blockers, statins, and Mg preparations). The lower sMg group showed a significantly higher prevalence of diabetes mellitus (DM), uric acid levels, and BNP levels compared with the higher sMg group. Kaplan\u2013Meier curve revealed a significantly higher probability of HF-related events in the lower sMg group compared with the higher sMg group (log-rank test,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u200a=\u200a.012). Multivariate Cox-proportional-hazard analysis revealed that the lower sMg group had significantly and independently higher probabilities of HF-related events compared with the higher sMg group (hazard ratio\u200a=\u200a2.37, 95% confidence intervals = 1.27\u20134.41,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u200a=\u200a.007). We reclassified the risk of HF-related events after adding the lower sMg to the other prognostic factors (age, previous hospitalization for HF, DM, Ln-BNP); the continuous net reclassification improvement was 29.0% (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u200a=\u200a.041). sMg levels might provide important prognostic information in regard to HFpEF.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000017069","type":"journal-article","created":{"date-parts":[[2019,9,30]],"date-time":"2019-09-30T23:51:45Z","timestamp":1569887505000},"page":"e17069","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":29,"title":["Clinical significance of serum magnesium levels in patients with heart failure with preserved ejection fraction"],"prefix":"10.1097","volume":"98","author":[{"given":"Taiki","family":"Nishihara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiichiro","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Sueta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichiro","family":"Fujisue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Usuku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumi","family":"Oike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Takae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Arima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Araki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiji","family":"Takashio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taishi","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Soejima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Kawano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Kaikita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Tsujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2019,9]]},"reference":[{"key":"R1-20260519","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.clnu.2009.04.024","article-title":"ESPEN guidelines on parenteral nutrition: intensive care","volume":"28","author":"Singer","year":"2009","journal-title":"Clin Nutr"},{"key":"R2-20260519","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1097\/CCM.0000000000001525","article-title":"Guidelines for the provision and assessment of nutrition support therapy in the adult critically ill patient: Society of Critical Care Medicine (SCCM) and American Society for Parenteral and Enteral Nutrition (A.S. P. E. N.)","volume":"44","author":"Taylor","year":"2016","journal-title":"Crit Care Med"},{"key":"R3-20260519","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3945\/ajcn.112.053132","article-title":"Circulating and dietary magnesium and risk of cardiovascular disease: a systematic review and meta-analysis of prospective studies\u2013","volume":"98","author":"Del Gobbo","year":"2013","journal-title":"Am J Clin Nutr"},{"key":"R4-20260519","doi-asserted-by":"crossref","first-page":"756","DOI":"10.3945\/ajcn.114.085167","article-title":"Serum magnesium, phosphorus, and calcium are associated with risk of incident heart failure: the Atherosclerosis Risk in Communities (ARIC) study","volume":"100","author":"Lutsey","year":"2014","journal-title":"Am J Clin Nutr"},{"key":"R5-20260519","doi-asserted-by":"crossref","first-page":"e000114","DOI":"10.1161\/JAHA.113.000114","article-title":"Dietary and plasma magnesium and risk of coronary heart disease among women","volume":"2","author":"Chiuve","year":"2013","journal-title":"J Am Heart Assoc"},{"key":"R6-20260519","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/0140-6736(92)91828-V","article-title":"Intravenous magnesium sulphate in suspected acute myocardial infarction: results of the second Leicester Intravenous Magnesium Intervention Trial (LIMIT-2)","volume":"339","author":"Woods","year":"1992","journal-title":"Lancet"},{"key":"R7-20260519","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S0140-6736(95)90865-X","article-title":"ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group","volume":"345","year":"1995","journal-title":"Lancet"},{"key":"R8-20260519","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/S0140-6736(02)11278-5","article-title":"Magnesium in Coronaries Trial I. Early administration of intravenous magnesium to high-risk patients with acute myocardial infarction in the Magnesium in Coronaries (MAGIC) Trial: a randomised controlled trial","volume":"360","year":"2002","journal-title":"Lancet"},{"key":"R9-20260519","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1093\/eurjhf\/hfp103","article-title":"The prognostic significance of heart failure with preserved left ventricular ejection fraction: a literature-based meta-analysis","volume":"11","author":"Somaratne","year":"2009","journal-title":"Eur J Heart Fail"},{"key":"R10-20260519","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1093\/eurheartj\/ehr254","article-title":"The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis","volume":"33","year":"2012","journal-title":"Eur Heart J"},{"key":"R11-20260519","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1253\/circj.CJ-15-0878","article-title":"Low-normal serum sodium and heart failure-related events in patients with heart failure with preserved left ventricular ejection fraction","volume":"80","author":"Kusaka","year":"2016","journal-title":"Circ J"},{"key":"R12-20260519","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1093\/ajh\/hpy101","article-title":"Serum potassium and cardiovascular events in heart failure with preserved left ventricular ejection fraction patients","volume":"31","author":"Nishihara","year":"2018","journal-title":"Am J Hypertens"},{"key":"R13-20260519","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/ehf2.12070","article-title":"The clinical significance of plasma neopterin in heart failure with preserved left ventricular ejection fraction","volume":"3","author":"Yamamoto","year":"2016","journal-title":"ESC Heart Fail"},{"key":"R14-20260519","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/ejhf.559","article-title":"Clinical significance of pulse pressure in patients with heart failure with preserved left ventricular ejection fraction","volume":"18","author":"Tokitsu","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"R15-20260519","doi-asserted-by":"crossref","DOI":"10.1093\/ajh\/hpz108","article-title":"H2FPEF Score as a Prognostic Value in HFpEF patients","author":"Sueta","year":"2019","journal-title":"Am J Hypertens"},{"key":"R16-20260519","doi-asserted-by":"crossref","first-page":"e002698","DOI":"10.1161\/CIRCHEARTFAILURE.115.002698","article-title":"Relation of magnesium intake with cardiac function and heart failure hospitalizations in black adults: the Jackson heart study","volume":"9","author":"Taveira","year":"2016","journal-title":"Circ Heart Fail"},{"key":"R17-20260519","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1007\/s10654-016-0164-4","article-title":"Serum magnesium and risk of new onset heart failure in men: the Kuopio ischemic heart disease study","volume":"31","author":"Kunutsor","year":"2016","journal-title":"Eur J Epidemiol"},{"key":"R18-20260519","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1161\/ATVBAHA.117.309182","article-title":"Magnesium counteracts vascular calcification: passive interference or active modulation?","volume":"37","author":"Ter Braake","year":"2017","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R19-20260519","article-title":"Nomenclature and criteria for diagnosis of diseases of the heart and great vessels","year":"1979","journal-title":"Little, Brown Medical Division"},{"key":"R20-20260519","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1161\/CIRCHEARTFAILURE.111.962654","article-title":"Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial","volume":"4","author":"Anand","year":"2011","journal-title":"Circ Heart Fail"},{"key":"R21-20260519","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1056\/NEJMoa051530","article-title":"Outcome of heart failure with preserved ejection fraction in a population-based study","volume":"355","author":"Bhatia","year":"2006","journal-title":"N Engl J Med"},{"key":"R22-20260519","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1111\/j.1532-5415.1995.tb05570.x","article-title":"Heart failure with normal systolic function: a common disorder in older people","volume":"43","author":"Tresch","year":"1995","journal-title":"J Am Geriatr Soc"},{"key":"R23-20260519","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1161\/CIRCULATIONAHA.110.011031","article-title":"Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction","volume":"124","author":"Zile","year":"2011","journal-title":"Circulation"},{"key":"R24-20260519","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1001\/jama.2013.905","article-title":"Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial","volume":"309","author":"Edelmann","year":"2013","journal-title":"JAMA"},{"key":"R25-20260519","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1093\/eurjhf\/hfs141","article-title":"Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese Diastolic Heart Failure Study (J-DHF)","volume":"15","author":"Yamamoto","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"R26-20260519","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1093\/eurheartj\/ehl250","article-title":"The perindopril in elderly people with chronic heart failure (PEP-CHF) study","volume":"27","author":"Cleland","year":"2006","journal-title":"Eur Heart J"},{"key":"R27-20260519","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","article-title":"Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial","volume":"362","author":"Yusuf","year":"2003","journal-title":"Lancet"},{"key":"R28-20260519","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1056\/NEJMoa0805450","article-title":"Irbesartan in patients with heart failure and preserved ejection fraction","volume":"359","author":"Massie","year":"2008","journal-title":"N Engl J Med"},{"key":"R29-20260519","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1056\/NEJMoa1510774","article-title":"Isosorbide mononitrate in heart failure with preserved ejection fraction","volume":"373","author":"Redfield","year":"2015","journal-title":"N Engl J Med"},{"key":"R30-20260519","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/S0140-6736(12)61227-6","article-title":"The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial","volume":"380","author":"Solomon","year":"2012","journal-title":"Lancet"},{"key":"R31-20260519","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1093\/ajh\/hpv015","article-title":"LCZ696, angiotensin II receptor-neprilysin inhibitor, ameliorates high-salt-induced hypertension and cardiovascular injury more than valsartan alone","volume":"28","author":"Kusaka","year":"2015","journal-title":"Am J Hypertens"},{"key":"R32-20260519","first-page":"655","article-title":"Cardioprotective effects of LCZ696 (sacubitril\/valsartan) after experimental acute myocardial infarction","volume":"2","author":"Ishii","year":"2017","journal-title":"JACC"},{"key":"R33-20260519","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"R34-20260519","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N Engl J Med"},{"key":"R35-20260519","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1001\/jamacardio.2018.2936","article-title":"One-year safety and clinical outcomes of a transcatheter interatrial shunt device for the treatment of heart failure with preserved ejection fraction in the reduce elevated left atrial pressure in patients with heart failure (REDUCE LAP-HF I) trial: a randomized clinical trial","volume":"3","author":"Shah","year":"2018","journal-title":"JAMA Cardiol"},{"key":"R36-20260519","doi-asserted-by":"crossref","first-page":"e5406","DOI":"10.1097\/MD.0000000000005406","article-title":"The association of serum magnesium and mortality outcomes in heart failure patients: a systematic review and meta-analysis","volume":"95","author":"Angkananard","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"R37-20260519","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0002-9149(00)01263-7","article-title":"Magnesium use in the treatment of acute myocardial infarction in the United States (observations from the Second National Registry of Myocardial Infarction)","volume":"87","author":"Ziegelstein","year":"2001","journal-title":"Am J Cardiol"},{"key":"R38-20260519","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1136\/heart.89.4.411","article-title":"Serum magnesium aberrations in furosemide (frusemide) treated patients with congestive heart failure: pathophysiological correlates and prognostic evaluation","volume":"89","author":"Cohen","year":"2003","journal-title":"Heart"},{"key":"R39-20260519","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.ijcard.2008.05.006","article-title":"Low serum magnesium and cardiovascular mortality in chronic heart failure: a propensity-matched study","volume":"136","author":"Adamopoulos","year":"2009","journal-title":"Int J Cardiol"},{"key":"R40-20260519","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1056\/NEJMra021498","article-title":"Heart failure","volume":"348","author":"Jessup","year":"2003","journal-title":"N Engl J Med"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000017069","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T16:00:48Z","timestamp":1779206448000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000017069"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":40,"journal-issue":{"issue":"38","published-online":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000017069","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"2019-05-02","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-08-12","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}